164 related articles for article (PubMed ID: 26888610)
1. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature.
Ter Wengel PV; Martin E; Gooren L; Den Heijer M; Peerdeman SM
Andrologia; 2016 Dec; 48(10):1130-1137. PubMed ID: 26888610
[TBL] [Abstract][Full Text] [Related]
2. Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report.
Pozzati E; Zucchelli M; Schiavina M; Contini P; Foschini MP
Surg Neurol; 2007 Dec; 68(6):671-674. PubMed ID: 17586005
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment.
Kalamarides M; Peyre M
World Neurosurg; 2017 May; 101():814.e7-814.e10. PubMed ID: 28300711
[TBL] [Abstract][Full Text] [Related]
4. Radiological evolution of progestogen-induced meningioma: A monocentric retrospective study.
Ahmed-Khalifa T; Gillet R; Blonski M; Rech F; Fresse A; Gillet P; Taillandier L; Petitpain N
Fundam Clin Pharmacol; 2023 Aug; 37(4):868-878. PubMed ID: 36692232
[TBL] [Abstract][Full Text] [Related]
5. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy.
Deipolyi AR; Han SJ; Parsa AT
J Clin Neurosci; 2010 Oct; 17(10):1324-6. PubMed ID: 20594855
[TBL] [Abstract][Full Text] [Related]
6. Gender-affirming hormone therapy associated with multiple meningiomas and atypical histology in a transgender woman.
Millward CP; Phillips E; Alalade AF; Gilkes CE
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34261631
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
8. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
9. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
Cebula H; Pham TQ; Boyer P; Froelich S
Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
[No Abstract] [Full Text] [Related]
10. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
11. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual.
Bergoglio MT; Gómez-Balaguer M; Almonacid Folch E; Hurtado Murillo F; Hernández-Mijares A
Endocrinol Nutr; 2013 May; 60(5):264-7. PubMed ID: 23022362
[TBL] [Abstract][Full Text] [Related]
13. Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy.
Gruber TJ; Fabiano AJ; Deeb G; Lele SB; Fenstermaker RA
World Neurosurg; 2011 Nov; 76(5):477.e16-20. PubMed ID: 22152580
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
Malaize H; Samoyeau T; Zanello M; Roux A; Benzakoun J; Peeters S; Zah-Bi G; Edjlali M; Tauziede-Espariat A; Dezamis E; Parraga E; Chrétien F; Varlet P; Plu-Bureau G; Oppenheim C; Pallud J
J Neurooncol; 2021 Apr; 152(2):279-288. PubMed ID: 33449307
[TBL] [Abstract][Full Text] [Related]
15. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.
Apra C; Roblot P; Alkhayri A; Le Guérinel C; Polivka M; Chauvet D
J Neurooncol; 2020 Aug; 149(1):95-101. PubMed ID: 32705456
[TBL] [Abstract][Full Text] [Related]
16. Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C
AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802
[TBL] [Abstract][Full Text] [Related]
17. Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report.
Gruber T; Dare AO; Balos LL; Lele S; Fenstermaker RA
J Neurosurg; 2004 Feb; 100(2):328-31. PubMed ID: 15086241
[TBL] [Abstract][Full Text] [Related]
18. Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation.
Florea SM; Passeri T; Abbritti R; Bernat AL; Fontanel S; Yoldjian I; Funck-Brentano T; Weill A; Mandonnet E; Froelich S
J Neurosurg; 2023 Oct; 139(4):944-952. PubMed ID: 36883659
[TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy for fertility and huge meningioma: a purely random association?
Frassanito P; De Bonis P; Mattogno PP; Novello M; Anile C
Acta Neurol Belg; 2012 Sep; 112(3):299-301. PubMed ID: 22426675
[TBL] [Abstract][Full Text] [Related]
20. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
